Univo (Unvmed.com), the complete solution for medical cannabis distribution, announces the development of its state-of-the-art facility and an investment by Hagag Group worth NIS 6 million. Univo is one of the few medical cannabis companies in the world to hold all four licenses for cultivation, research and development, production, and distribution of their own cannabis products.
The cannabis market is expected to expand globally in 2019. Medical cannabis has become a sought after natural remedy to treat a wide range of medical issues. With more countries legalizing it around the world, medical cannabis is gaining popularity as a viable treatment option. However, there is still an element of skepticism involved; with cannabis companies dumping excessive amounts of THC and CBD into products, there are dangerous risks associated with this flourishing industry. So, how do we find clarity through all the smoke? Univo conducts all of its research in house and will continue its progress in their new 750m² facility with an R&D laboratory on site. Using this facility, which is currently under construction, Univo will continue to grow high-quality cannabis, while developing a diverse product line using innovative technologies and unique genetics of medical cannabis strains.
Univo has the ability to create medical-grade products to help with neurodegenerative disorders, autoimmune and inflammatory diseases, metabolic disease, and neurological disorders. Univos vision is to make pain management easy with proposed products that will be able to soothe children living with ADHD, relieve tooth and gum pain, reduce oral pain caused by infections and cavities, and to alleviate skin allergies and pain caused by intestinal issues.
Additionally, Ido Hagag, real estate developer and owner of Hagag Group, has invested NIS 6 million in Univo. After examining several investment options in the field of cannabis, Hagag acquired 11.6% of the company, citing Univos impressive licenses, first-class professionalism, and comprehensive infrastructure for operations in Israel and internationally.
The global market shift from recreational to legalized cannabis, along with Univos unique position of seed-to-market control, will position our company as a prominent leader in research and development of medical cannabis products, says Golan Bitton, CEO of Univo. Our state-of-the-art facility will allow us to continue using groundbreaking techniques, in hopes of growing high-quality cannabis and developing a diverse product line.
Univo is based in Israel, where low production and distribution costs have made the nation a leading exporter of medical cannabis. These low costs allow for easy distribution of medical cannabis products to international markets, especially since the Israeli Knesset, or parliament, legalized its worldwide export in January.
Led by CEO Golan Bitton and a dedicated team of professional biochemists, Univo, founded in 2016, will grow high quality cannabis and develop diverse products using innovative technologies and unique genetics of medical cannabis strains. They are currently developing a highly sophisticated GAP greenhouse and a GMP state-of-the-art manufacturing facility to cultivate a wide variety of cannabis strains to meet their goal of treating a wide range of medical needs.
Company Media Contact:
Blonde 2.0 for Univo